Morphic Medical Announces Leadership Transition with New CEO Appointment
On August 5, 2025, Morphic Medical, a pioneering MedTech company focused on minimally invasive treatments for obesity and cardiometabolic disorders, shared important news concerning its leadership transition. Joe Virgilio, after five years of dedicated service as the CEO, has announced his departure from this pivotal role. His tenure was marked by significant achievements, including critical milestones in product development, production enhancements, and organizational growth. Notably, he oversaw the successful submission for regulatory approval of the company's innovative therapy, RESET®, under EU MDR guidelines, which was achieved in July of the same year.
Morphic Medical’s Board of Directors expressed their gratitude towards Virgilio, recognizing his leadership, vision, and commitment to advancing patient care and innovation. The board then announced that Mike Gutteridge will take over as the company’s new CEO. Gutteridge brings extensive experience in bariatric endoscopy and had previously held the position of Vice President of Therapy Development and Commercial Operations at Morphic. In this prior role, he was instrumental in crafting the go-to-market strategy for the RESET® product, which promises a non-surgical alternative treatment for severe obesity and associated cardiometabolic risks like Type 2 diabetes.
In his statement, Mark Lerdal, Board Chair, emphasized the invaluable role that Joe has played in shaping Morphic Medical, portraying him as a driving force in the company’s rise and success. Joe's leadership defined much of the company's history, and his departure is both a loss and a stepping stone for the company. As he reflected on his time leading Morphic, Joe described the experience as a privilege and a point of pride. He conveyed confidence in the company’s future under Gutteridge's leadership, expressing a commitment to assist in a seamless transition.
Mike Gutteridge welcomed his new role, expressing honor and excitement to step into the CEO position. He acknowledged Virgilio’s support and conveyed enthusiasm about leveraging over 30 years of experience in the MedTech sector, particularly focusing on clinical innovation, market development, and reimbursement strategies, to guide Morphic into its next growth phase. He is eager to drive targeted global market expansion, enhance market penetration, and deepen the commitment to improving patients' lives through effective, sustainable therapies.
As Gutteridge prepares to lead Morphic, he intends to build upon the company’s foundation in gastrointestinal metabolic health while promoting a culture of agility, purpose, and partnership within the team and the broader clinical and research community. His vision seeks to ensure that Morphic's advanced technologies reach those who need them the most while creating lasting value through responsible growth.
The leadership transition will be carefully planned over the coming months, ensuring continuity across all areas of stakeholder and partnership engagement, crucial for sustained organizational momentum.
Founded in 2003 and headquartered in Boston, Massachusetts, Morphic Medical is recognized for developing RESET®, an endoscopically delivered therapy aimed at providing a non-surgical treatment option for morbid obesity, particularly when complicated by cardiometabolic factors. While RESET® is not yet approved for sale in the United States and is only available for research purposes, Morphic Medical’s innovations signal a significant advancement in medical technology aimed at tackling obesity and related health risks. Further information on Morphic Medical can be found on their official website, morphicmedical.com, or through their social media platforms on Twitter and LinkedIn.
Morphic Medical’s Board of Directors expressed their gratitude towards Virgilio, recognizing his leadership, vision, and commitment to advancing patient care and innovation. The board then announced that Mike Gutteridge will take over as the company’s new CEO. Gutteridge brings extensive experience in bariatric endoscopy and had previously held the position of Vice President of Therapy Development and Commercial Operations at Morphic. In this prior role, he was instrumental in crafting the go-to-market strategy for the RESET® product, which promises a non-surgical alternative treatment for severe obesity and associated cardiometabolic risks like Type 2 diabetes.
In his statement, Mark Lerdal, Board Chair, emphasized the invaluable role that Joe has played in shaping Morphic Medical, portraying him as a driving force in the company’s rise and success. Joe's leadership defined much of the company's history, and his departure is both a loss and a stepping stone for the company. As he reflected on his time leading Morphic, Joe described the experience as a privilege and a point of pride. He conveyed confidence in the company’s future under Gutteridge's leadership, expressing a commitment to assist in a seamless transition.
Mike Gutteridge welcomed his new role, expressing honor and excitement to step into the CEO position. He acknowledged Virgilio’s support and conveyed enthusiasm about leveraging over 30 years of experience in the MedTech sector, particularly focusing on clinical innovation, market development, and reimbursement strategies, to guide Morphic into its next growth phase. He is eager to drive targeted global market expansion, enhance market penetration, and deepen the commitment to improving patients' lives through effective, sustainable therapies.
As Gutteridge prepares to lead Morphic, he intends to build upon the company’s foundation in gastrointestinal metabolic health while promoting a culture of agility, purpose, and partnership within the team and the broader clinical and research community. His vision seeks to ensure that Morphic's advanced technologies reach those who need them the most while creating lasting value through responsible growth.
The leadership transition will be carefully planned over the coming months, ensuring continuity across all areas of stakeholder and partnership engagement, crucial for sustained organizational momentum.
About Morphic
Founded in 2003 and headquartered in Boston, Massachusetts, Morphic Medical is recognized for developing RESET®, an endoscopically delivered therapy aimed at providing a non-surgical treatment option for morbid obesity, particularly when complicated by cardiometabolic factors. While RESET® is not yet approved for sale in the United States and is only available for research purposes, Morphic Medical’s innovations signal a significant advancement in medical technology aimed at tackling obesity and related health risks. Further information on Morphic Medical can be found on their official website, morphicmedical.com, or through their social media platforms on Twitter and LinkedIn.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.